When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Do you weigh any specific clinical or disease factors?
Community PollStarted
When do you typically consider using Dato-DXd for patients with EGFR-mutated NSCLC?
43 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · Northwestern Medical Group
Answered on
I would select Dato-DXD for patients with EGFR-mutated NSCLC, after I have trialed osimertinib and amivantamab in the first- and second-line setting. I usually include chemotherapy with one of these two medications as well. If a patient fails both of these treatments, I would consider Dato-DXD at th...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University Of Texas Southwestern Medical Center At Dallas
Answered on
Dato-DXd is typically selected for patients with EGFR-mutated non-small cell lung cancer (NSCLC) after they have progressed on both prior EGFR-directed therapy (such as osimertinib) and platinum-based chemotherapy.
Factors to consider:
- EGFR mutation status: Dato-DXd is effective for NSCLC with EGFR...
Join for free or sign in to see the full answer